The US has pledged up to $1.2 billion from the Biomedical Advanced Research and Development Authority for 300 million doses of the experimental COVID-19 vaccine AZD1222 being developed jointly by AstraZeneca and the University of Oxford. The target availability date of the first doses could be as early as October, according to an HHS statement.
US pledges $1.2B for 300M doses of AstraZeneca COVID-19 vaccine
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.